2001
Time-Limited Assertive Community Treatment for Homeless Persons With Severe Mental Illness
Rosenheck RA, Dennis D. Time-Limited Assertive Community Treatment for Homeless Persons With Severe Mental Illness. JAMA Psychiatry 2001, 58: 1073-1080. PMID: 11695955, DOI: 10.1001/archpsyc.58.11.1073.Peer-Reviewed Original ResearchConceptsSevere mental illnessMental illnessService useHealth statusOutpatient health service useSubstance abuseAssertive community treatment modelHealth service useAssertive community treatmentMental health statusRandom-effects modelCommunity treatment modelHospital daysPublic support paymentsCommunity treatmentCommunity careIllnessMental healthMore daysMonthsTreatment modelHomeless personsEffects modelAnnual cohortsHomeless clients
1999
Shifting to Outpatient Care? Mental Health Care Use and Cost Under Private Insurance
Leslie D, Rosenheck R. Shifting to Outpatient Care? Mental Health Care Use and Cost Under Private Insurance. American Journal Of Psychiatry 1999, 156: 1250-1257. PMID: 10450268, DOI: 10.1176/ajp.156.8.1250.Peer-Reviewed Original ResearchConceptsMental health servicesMental health costsOutpatient careInpatient careTreatment daysService useHealth servicesMental health care useOutpatient mental health costsOutpatient service useInpatient service useProportion of enrolleesHealth care usePatterns of careHealth costsHealth care costsHospital daysIll patientsInpatient costsOutpatient claimsPrimary diagnosisCare useModerate depressionStudy groupOutpatient servicesChanges in Inpatient Mental Health Utilization and Costs in a Privately Insured Population, 1993 to 1995
Leslie D, Rosenheck R. Changes in Inpatient Mental Health Utilization and Costs in a Privately Insured Population, 1993 to 1995. Medical Care 1999, 37: 457-468. PMID: 10335748, DOI: 10.1097/00005650-199905000-00005.Peer-Reviewed Original ResearchConceptsHospital daysMental health utilizationInpatient claims dataProportion of enrolleesAnnual hospital daysHealth care providersMental health servicesQuality of careHealth care costsMental health costsMarketScan databaseInpatient costsHealth utilizationPatient satisfactionPrimary diagnosisModerate depressionTreatment daysCare providersClaims dataPsychiatric carePatientsCare costsDiem costsHealth servicesDiagnostic groups
1998
Predictors of differential response to clozapine and haloperidol
Rosenheck R, Lawson W, Crayton J, Cramer J, Xu W, Thomas J, Stolar M, Charney D, Schizophrenia F. Predictors of differential response to clozapine and haloperidol. Biological Psychiatry 1998, 44: 475-482. PMID: 9777179, DOI: 10.1016/s0006-3223(98)00117-6.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAntipsychotic AgentsClozapineDouble-Blind MethodDrug ResistanceFemaleHaloperidolHumansMalePsychiatric Status Rating ScalesQuality of LifeRacial GroupsSchizophreniaSchizophrenic PsychologySocial SupportTreatment OutcomeUnited StatesUnited States Department of Veterans AffairsConceptsQuality of lifeThree-month outcomeOnset of schizophreniaSeverity of symptomsGreater symptom reductionGreater improvementRefractory patientsRefractory schizophreniaClozapine treatmentHospital daysClinical predictorsExtrapyramidal symptomsHospitalized patientsClinical trialsBaseline predictorsSample patientsSide effectsSymptom reductionClozapinePatientsSymptomsHigher symptomsHigh levelsHaloperidolMultiple regression analysis